Show simple item record

dc.contributor.authorCornell, R.F.
dc.contributor.authorBachanova, V.
dc.contributor.authorD'Souza, A.
dc.date.accessioned2019-07-15T16:12:14Z
dc.date.available2019-07-15T16:12:14Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85006371447&doi=10.1016%2fj.bbmt.2016.10.010&partnerID=40&md5=ea7b6c9b1714e3bb6898845bd66a3b2e
dc.identifier.urihttp://hdl.handle.net/10713/9962
dc.description.abstractWaldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is characterized by lymphoplasmacytic proliferation, lymph node and spleen enlargement, bone marrow involvement, and IgM production. Treatment varies based on the extent and biology of disease. In some patients, the use of allogeneic hematopoietic cell transplantation (alloHCT) may have curative potential. We evaluated long-term outcomes of 144 patients who received adult alloHCT for WM/LPL. Data were obtained from the Center for International Blood and Marrow Transplant Research database (2001 to 2013). Patients received myeloablative(n = 67) or reduced-intensity conditioning (RIC; n = 67). Median age at alloHCT was 53 years, and median time from diagnosis to transplantation was 41 months. Thirteen percent (n = 18) failed prior autologous HCT. About half (n = 82, 57%) had chemosensitive disease at the time of transplantation, whereas 22% had progressive disease. Rates of progression-free survival, overall survival, relapse, and nonrelapse mortality at 5 years were 46%, 52%, 24%, and 30%, respectively. Patients with chemosensitive disease and better pretransplant disease status experienced significantly superior overall survival. There were no significant differences in progression-free survival based on conditioning (myeloablative, 50%, versus RIC, 41%) or graft source. Conditioning intensity did not impact treatment-related mortality or relapse. The most common causes of death were primary disease and graft-versus-host disease (GVHD). AlloHCT yielded durable survival in select patients with WM/LPL. Strategies to reduce mortality from GVHD and post-transplant relapse are necessary to improve this approach. Copyright 2017 The American Society for Blood and Marrow Transplantationen_US
dc.description.sponsorshipThe CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from various corporations.en_US
dc.description.urihttps://www.doi.org/10.1016/j.bbmt.2016.10.010en_US
dc.language.isoen_USen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofBiology of Blood and Marrow Transplantation
dc.subjectAllogeneic stem cell transplanten_US
dc.subjectRelapsed lymphomaen_US
dc.titleAllogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphomaen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.bbmt.2016.10.010
dc.identifier.pmid27789362


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record